C12N 15/1138
Against receptors or cell surface proteins
Official title: {against receptors or cell surface proteins}
C12N15/1138 (Against receptors or cell surface proteins) appears on 2,105 US grants and 4,301 published applications in this corpus.
Search patents in C12N- Granted patents
- 2,105
- Published applications
- 4,301
- Assignees
- 1,438
- Inventors
- 6,918
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 4 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 8 | 0 |
| 1997 | 26 | 0 |
| 1998 | 40 | 0 |
| 1999 | 37 | 0 |
| 2000 | 40 | 0 |
| 2001 | 39 | 4 |
| 2002 | 30 | 29 |
| 2003 | 29 | 121 |
| 2004 | 24 | 100 |
| 2005 | 15 | 134 |
| 2006 | 20 | 90 |
| 2007 | 15 | 109 |
| 2008 | 13 | 106 |
| 2009 | 38 | 152 |
| 2010 | 74 | 150 |
| 2011 | 79 | 160 |
| 2012 | 76 | 134 |
| 2013 | 95 | 136 |
| 2014 | 90 | 156 |
| 2015 | 104 | 175 |
| 2016 | 103 | 198 |
| 2017 | 112 | 188 |
| 2018 | 111 | 196 |
| 2019 | 113 | 202 |
| 2020 | 113 | 211 |
| 2021 | 130 | 247 |
| 2022 | 105 | 277 |
| 2023 | 84 | 253 |
| 2024 | 95 | 297 |
| 2025 | 123 | 293 |
| 2026 | 116 | 183 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Gene therapy for neurodegenerative disorders using polynucleotide silencing and replacement6 Oct 2026US 12,753,411 B2The Brigham and Women S Hospital, Inc.
- Compositions and methods for modifying a target nucleic acid6 Oct 2026US 12,753,412 B2The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
- Chimeric antigen receptors (CARs) targeting hematologic malignancies, compositions and methods of use thereof15 Sep 2026US 12,735,471 B2iCell Gene Therapeutics Inc.
- Use of FcgammaRIII inhibitor in preparation of medicament for treating pulmonary fibrosis15 Sep 2026US 12,735,489 B2Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences
- Targeting the human CCR5 locus as a safe harbor for the expression of therapeutic proteins15 Sep 2026US 12,735,711 B2The Board of Trustees of the Leland Stanford Junior University
- Antisense oligomer formulations8 Oct 2026US 2026/0308595 A1Stoke Therapeutics, Inc.
- Correction of the two most prevalent ush2a mutations by genome editing8 Oct 2026US 2026/0308596 A1Inserm (Institut National De La Sante Et De La Recherche Medicale)
- Methods of minimising effects of smoke exposure8 Oct 2026US 2026/0308597 A1Rage Biotech Pty Ltd
- Gene therapy8 Oct 2026US 2026/0308598 A1
- Gip activity modulators and orthostatic intolerance24 Sep 2026US 2026/0285992 A1Antag Therapeutics ApS
Most cited
By later US patents
- Antisense oligonucleotide modulation of multidrug resistance-associated protein841US 5,801,154 AIsis Pharmaceuticals, Inc. · 1998
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Oligonucleotides containing N-2 substituted purines621US 5,587,469 AIsis Pharmaceuticals, Inc. · 1996
- 2'deoxy-2'-alkylnucleotide containing nucleic acid521US 5,627,053 ARibozyme Pharmaceuticals, Inc. · 1997
- In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom267US 5,624,803 AThe Regents of the University of California · 1997